<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03895801</url>
  </required_header>
  <id_info>
    <org_study_id>IFX-1-P2.5</org_study_id>
    <nct_id>NCT03895801</nct_id>
  </id_info>
  <brief_title>Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.</brief_title>
  <acronym>IXchange</acronym>
  <official_title>A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InflaRx GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InflaRx GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy of IFX-1 treatment as replacement for
      glucocorticoid (GC) therapy in subjects with GPA and MPA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AAV is a group of potentially life-threatening autoimmune diseases. Preclinical data
      demonstrate that primed neutrophils are activated by ANCA and generate C5a that engages C5a
      receptors on neutrophils. Patients with ANCA-related disease have elevated plasma and urine
      levels of C5a in active disease but not in remission. IFX-1 is as a monoclonal antibody
      specifically binding to the soluble human complement split product C5a, which results in
      nearly complete blockade of C5a induced biological effects. Therefore, IFX-1 may be effective
      in the treatment of subjects with AAV.

      In this Phase II study of 20 to 81 subjects with GPA or MPA, IFX-1 will be administered in
      combination with reduced dose glucocorticoids or a placebo glucocorticoid compared with
      standard dose glucocorticoids.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving clinical response (reduction in Birmingham Vasculitis Activity Score [BVAS] of ≥50% compared to baseline and no worsening in any body system)</measure>
    <time_frame>Week 16</time_frame>
    <description>Efficacy Endpoint based on clinical response evaluated through BVAS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events (TEAE)</measure>
    <time_frame>Week 24</time_frame>
    <description>Safety endpoint: Number and percentage of subjects who had a TEAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events (SAEs)</measure>
    <time_frame>Week 24</time_frame>
    <description>Safety endpoint: Number and percentage of subjects with SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events of Special Interest (AESIs)</measure>
    <time_frame>Week 24</time_frame>
    <description>Safety endpoint: Number and percentage of subjects with AESIs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucocorticoid (GC)-induced toxicity of standard-dose GC and reduced-dose GC with IFX-1 treatment</measure>
    <time_frame>Week 24</time_frame>
    <description>Safety Endpoint: Glucocorticoid-induced toxicity as measured by the Glucocorticoid Toxicity Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic and pharmacodynamic modelling of IFX-1 treatment</measure>
    <time_frame>Week 24</time_frame>
    <description>Plasma concentration of IFX-1</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Polyangiitis, Granulomatosis With</condition>
  <arm_group>
    <arm_group_label>Group A Experimental + active comparator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IFX-1 + reduced dose GC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B Placebo + active comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo-IFX-1 + standard dose GC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C Experimental + placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IFX-1 + Placebo-GC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFX-1</intervention_name>
    <description>intravenously administered</description>
    <arm_group_label>Group A Experimental + active comparator</arm_group_label>
    <arm_group_label>Group C Experimental + placebo comparator</arm_group_label>
    <other_name>CaCP29</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-IFX-1</intervention_name>
    <description>intravenously administered</description>
    <arm_group_label>Group B Placebo + active comparator</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucocorticoid (GC)</intervention_name>
    <description>orally administered</description>
    <arm_group_label>Group A Experimental + active comparator</arm_group_label>
    <arm_group_label>Group B Placebo + active comparator</arm_group_label>
    <other_name>Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-Glucocorticoid (Placebo-GC)</intervention_name>
    <description>orally administered</description>
    <arm_group_label>Group C Experimental + placebo comparator</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of GPA or MPA

          -  Have ≥ 1 &quot;major&quot; item, or ≥ 3 other items, or ≥ 2 renal items on the Birmingham
             Vasculitis Activity Score Version 3 (BVASv3).

          -  Newly diagnosed or relapsed GPA or MPA that requires treatment with CYC or RTX plus
             GCs.

          -  Glomerular filtration rate ≥ 20 mL/min/1.73 m².

        Exclusion Criteria:

          -  Any other multi-system autoimmune disease.

          -  Require mechanical ventilation at screening.

          -  Known hypersensitivity to any investigational medicinal product and/or any excipient.

          -  Rare hereditary problems of galactose intolerance, total lactase deficiency or
             glucose-galactose malabsorption.

          -  Have required management of infections, as follows (a) Chronic infection requiring
             anti-infective therapy within 3 months before screening. (b) Use of intravenous
             antibacterials, antivirals, anti-fungals, or anti-parasitic agents within 30 days of
             screening

          -  Current and/or history (within the previous 5 years) of drug and/or alcohol abuse
             and/or dependence.

          -  Evidence of Hep B, C and/ or HIV infection. Only subjects with documented negative
             historical results (within 4 weeks before screening) for Hep B,C Virus and HIV or a
             negative test by Screening can be included into the study.

          -  Abnormal laboratory findings at screening

          -  Current or history of malignancy, lymphoproliferative, or myeloproliferative disorder

          -  Received CYC or RTX within 12 weeks before screening or within 12 weeks before CYC or
             RTX is started for remission induction within 2 weeks before screening.

          -  Received &gt; 3 g cumulative intravenous GCs within 4 weeks before screening.

          -  Received an oral daily dose of a GC of &gt; 10 mg prednisone-equivalent for more than 6
             weeks continuously prior to screening.

          -  Received an oral daily dose of a GC of &gt; 80 mg prednisone equivalent within 2 weeks
             before screening.

          -  Received a CD20 inhibitor, anti-tumor necrosis factor treatment, abatacept,
             alemtuzumab, any other experimental or biological therapy, intravenous immunoglobulin
             (Ig) or plasma exchange, antithymocyte globulin, or required renal dialysis within 12
             weeks before screening.

          -  Received a live vaccination within 4 weeks before screening

          -  Either active or latent tuberculosis treatment is ongoing.

          -  Pregnant or lactating.

          -  Abnormal electrocardiogram.

          -  Female subjects of childbearing potential unwilling or unable to use a highly
             effective method of contraception

          -  Participation in an investigational clinical study during the 12 weeks before
             screening.

          -  Male subjects with female partners of childbearing potential unwilling to use
             contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anja Pfaff, PhD</last_name>
    <role>Study Director</role>
    <affiliation>InflaRx GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Korinna Pilz, MD</last_name>
    <phone>+49 3641 508180</phone>
    <email>info@inflarx.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anja Pfaff, PhD</last_name>
    <phone>+49 3641 508180</phone>
    <email>info@inflarx.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Lüttich</name>
      <address>
        <city>Lüttich</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hradec Králové</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Prague</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Praha</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Kopenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>France</name>
      <address>
        <city>Herbault</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Paris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Vienne</name>
      <address>
        <city>Vienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Jena</name>
      <address>
        <city>Jena</city>
        <state>Thüringen</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Aachen AOeR</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Nordrhein Westfalen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Kirchheim unter Teck</name>
      <address>
        <city>Kirchheim unter Teck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Koeln</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Georg GmbH</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigshafen</name>
      <address>
        <city>Ludwigshafen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Nordrhein Westfalen</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria &quot;Policlinico - Vittorio Emanuele&quot; (Presidio Vittorio Emanuele)</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Messina</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Italy</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Pisa</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Verona</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SAIH &quot;Kemerovo Regional Clinical Hospital&quot;</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FSAEI HE &quot; First Moscow State Medical University n.a. I.M. Sechenov&quot; of the MoH of the RF</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SBIH of Moscow region &quot; Moscow Regional Scientific and Research Clinical Institute n.a. M.F. Vladimi</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SIH &quot;Regional Clinical Hospital &quot;</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SBIH &quot;Orenburg Regional Clinical Hospital&quot;</name>
      <address>
        <city>Orenburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SBIH of Republic Kareliya &quot;Republican Hospital n.a. V.A. Baranov&quot;</name>
      <address>
        <city>Petrozavodsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SIH &quot;Saratov City Clinical Hospital # 12&quot;</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SBIH of Yaroslavl region &quot; Regional Clinical Hospital &quot;</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Sevilla</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Göteborg</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Stockholm</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Uppsala</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>United Kingdom</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Cambridge</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Cardiff</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Lancashire</name>
      <address>
        <city>Fulwood</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Leicestershire</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Portsmouth</name>
      <address>
        <city>Portsmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Berkshire Hospital</name>
      <address>
        <city>Reading</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northern General Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 8, 2019</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2019</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>granulomatosis</keyword>
  <keyword>polyangiitis</keyword>
  <keyword>corticosteroid</keyword>
  <keyword>replacement</keyword>
  <keyword>glucocorticoid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Microscopic Polyangiitis</mesh_term>
    <mesh_term>Systemic Vasculitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

